Review of NICE Technology Appraisal Guidance No 101; Docetaxel for the treatment of hormone refractory prostate cancer

Review decision

The Institute was proposing that a review of the guidance should be deferred to June 2013.

During consultation, the majority of comments received by the Institute agreed with the proposal put forward. After consideration of all of the comments (included in appendix A), the Institute’s Guidance Executive has decided to proceed with the proposal. We will therefore schedule a review to again assess the evidence in April 2013.